ArticleScientific reports2025
Mechanistic insights into the effects of Tris-2-butoxyethyl phosphate on multiple cancers using network toxicology and molecular docking.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hederagenin Promotes Sorafenib Sensitivity in Hepatocellular Carcinoma Through Suppressing SLC7A11 Expression and Inducing Ferroptosis.Food science & nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study investigates the potential mechanisms by which Tris(2-butoxyethyl) phosphate (TBEP) may contribute to the development and progression of human malignancies. Fourteen representative cancer types were selected to explore the molecular pathways through which TBEP may exert its effects. By integrating network toxicology, molecular docking, and molecular dynamics (MD) simulations, we elucidated the underlying mechanisms of TBEP-related carcinogenicity. Potential targets associated with these malignancies were identified using multiple databases, including Public Chemical Database (PubChem), Search Tool for Interacting Chemicals (STITCH), SwissTargetPrediction, The Human Gene Database (GeneCards), the Online Mendelian Inheritance in Man (OMIM), and the Therapeutic Target Database (TTD). Core targets were further screened through STRING analysis and visualized using Cytoscape software. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were then performed to characterize the biological functions and pathways involved Three-dimensional structures of the core target proteins were retrieved from the Protein Data Bank (PDB), optimized using PyMOL (version 3.0.3), and subjected to molecular docking with AutoDock Vina to assess their binding affinities with TBEP. The stability of the resulting protein-ligand complexes was validated through MD simulations using GROMACS 2022. Finally, the relevance of the identified cancer types was confirmed using The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases. Overall, our findings suggest that TBEP may promote cancer development by interacting with key targets such as SRC and CASP3 and modulating critical signaling pathways. This study provides new insights into the potential carcinogenic mechanisms of TBEP and offers a theoretical foundation for future prevention and therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.